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New and emerging advances in colorectal cancer (CRC) treatment combined with limited health 
care resources highlight the need for detailed decision-analytic models to evaluate costs, survival 
and quality adjusted life-years. The objectives of this article were to estimate the expected lifetime 
treatment cost of CRC for an average 70-year-old patient and to test the applicability and 
flexibility of a model in predicting survival and costs of changing treatment scenarios.  
The analyses were based on a validated semi-Markov model using data from a Norwegian 
observational study (2049 CRC-patients) to estimate transition probabilities and the proportion 
resected. In addition, inputs from the Norwegian Patient Registry, guidelines, literature, and 
expert opinions were used to estimate resource use.  
We found that the expected lifetime treatment cost for a 70-year-old CRC patient was €47,300 
(CRC stage I €26,630, II €38,130, III €56,800, and IV €69,890). Altered use of palliative 
chemotherapy would increase the costs by up to 29%. A 5 percentage point reduction in 
recurrence rate for stages I–III would reduce the costs by 5.3% and increase overall survival by 
8.2 months. Given the Norwegian willingness to pay threshold per QALY gained, society’s 
willingness to pay for interventions that could result in such a reduction was on average €28,540 
per CRC patient. The life years gained by CRC treatment were 6.05 years. 
The overall CRC treatment costs appear to be low compared to the health gain, and the use of 
palliative chemotherapy can have a major impact on cost. The model was found to be flexible 
and applicable for estimating the cost and survival of several CRC treatment scenarios.  






Cancer is a major cause of morbidity and mortality in the Western world, with colorectal cancer (CRC) 
being the second most common cancer in women and the third most common cancer in men [1]. Norway 
is among the countries in the world with the highest incidence of CRC [2]. As the number of CRC cases 
increases with an ageing population, and new costly drugs are launched in the market, we expect a 
substantial increase in the cost of CRC treatment. For healthcare providers making decisions regarding 
reimbursement, it is important to consider the cost-effectiveness of preventive and treatment alternatives 
in order to optimise resource allocation.   
Decision-analytic models are useful to achieve optimal allocation of resources because these models can (i) 
provide information about the burden of diseases, (ii) within a certain disease identify treatment strategies 
with potential health gains, and (iii) evaluate the cost-effectiveness of new treatment options (Table 1). 
Regarding (i), decision-analytic models can be used in comparative cost-of-illness studies, which compare 
the cost of CRC treatment with the cost of treating other diseases [3]. Regarding (ii), for new ideas and 
innovations in surgery, chemotherapy, screening, and primary prevention, a decision-analytic model is 
useful for exploring the potential incremental cost and incremental health gain (reduced mortality, 
recurrence rate, and health related quality of life). Based on these estimates and the willingness to pay 
(WTP) threshold (the value for an incremental health gain), we can identify the maximum acceptable 
amount to invest in these interventions. Furthermore, results from such explorative analyses can be used 
to evaluate budget impacts for the healthcare sector [4]. Regarding (iii), decision-analytic models are useful 
when estimating the cost-effectiveness of single or combined interventions both within and between 
intervention strategies such as surgery, chemotherapy, and screening.  
Table 1 
The first objective of this study was to estimate the expected lifetime cost and survival of CRC treatment 
for an average 70-year-old CRC patient based on a general, validated decision-analytic model [5]. The 
second objective was to explore the applicability and flexibility of the model by performing several 
analyses of changing CRC treatment strategies, the consequences of increasing the number of patients 
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receiving palliative chemotherapy (including antibodies), the consequences of decreasing the recurrence 
rate, and the effect of diagnosing CRC at an earlier stage (by screening or other measures). With these two 
objectives, we explored the general properties of the CRC decision-analytic model and how it contributed 
at all three levels as shown in Table 1.  
 
2. Methods  
 
We applied the perspective of the healthcare sector and included costs of diagnostic and staging 
investigations, surgery (major resection and palliative surgery without resection), treatment for 
complications, preoperative (neoadjuvant) and postoperative (adjuvant) treatment, follow up, curative 
treatment of recurrence, palliative treatment of recurrence and primarily non-resectable disease, and visits 
to general practitioners. We measured the health outcomes in both life years (LYs) and quality-adjusted 
life years (QALYs).   
 
2.1 The model 
In brief, the costs and survival in this paper were estimated based on a semi-Markov model, details of 
which were published in [5]. The flow of CRC patients was simulated in the model from CRC diagnosis at 
the age of 70 years through periods of treatment and healthy periods until the patients were 100 years of 
age or had died from CRC or other causes (Figure 1). Each arrow reflected the probability of an average 
CRC patient moving from one health state to another during one cycle or maintaining in the same health 
state (follow the loops). The patient entered the model at the time of primary diagnosis in one of the TNM 
stages (I, II, III or IV), and the first step included the costs of primary work-up and treatment during the 
first year after diagnosis. The following year, any patient who received curative treatment moved to the 
health state “disease free”, which means that the tumour had been resected and that there was no evidence 
of macro- or microscopic residual tumour (R0-resection) - locoregionally and no radiological evidence of 
distant metastases. Alternatively, the patient was not curable at the time of diagnosis (non-resectable 
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disease) and moved to the palliative health state or experienced recurrence after an apparently curative 
resection or died of CRC or other causes. From ‘disease free’, the patients could die of other causes or 
move to one of the three recurrence states. The majority of patients entering one of the three recurrence 
states (local and/or distant recurrence) received palliative chemotherapy. Some patients underwent 
resection with curative intent, often combined with (neo)adjuvant (radio)chemotherapy, and some 





For the majority of the patients in stage IV, the intent of treatment was palliation. Patients not eligible for 
any specific anti-cancer therapy, due to old age or poor general health, received supportive care until 
entering ‘Dead by CRC’. Palliative treatment mainly consisted of chemotherapy and/or targeted therapy 
(antibodies), but a small proportion was also offered radiotherapy. The treatment algorithm for 1st, 2nd, 
and 3rd lines of palliative chemotherapy is illustrated in Figure 2, which is a sub-model of the model in 
Figure 1. The treatment depended on age and health status (fragile), and there were several treatment 
options in each treatment line. When the disease progressed during the initial palliative drug treatment (1st 
line), a new treatment was usually offered (2nd line), and when the patient experienced additional 
progression a 3rd line of treatment could be offered [6, 7]. FLIRI is a combination of Irinotecan and 5-
fluorouracil/folinic acid (5-FU/FA), the latter of which was based on a Nordic protocol (Nordic FLv). 
FLOX is a therapeutic combination of Oxaliplatin and 5-FU/FA. The figures at each arrow in Figure 2 
indicate the conditional probability, and the figures in brackets express the joint (total) probability of 
receiving a certain type of treatment [5]. For each treatment in the decision tree, separate cost models were 
developed that included the costs of medication, CT scanning, complications, and treatment by nurses, 
pharmacists, and medical practitioners. The model was adjusted for non-compliance and discontinuation 
of chemotherapy, and this decision tree (Figure 2) was the basis for estimating the average cost of 





In the model, the duration of one cycle was set to one year, and for each health state, there was a cost 
model estimating the cost of the health service provided per person per year. We estimated the total CRC 
cost and the survival of an average CRC patient diagnosed at the age of 70 years. Survival and QALYs 
were half-cycle corrected. For costs, standard half-cycle corrections were not modelled but were modelled 
indirectly using empirical data to estimate CRC treatment cost considering compliance and mortality. Time 
dependency in the calculation of probabilities of recurrence and death was captured in the model by 
including tunnel states.  
 
 
2.2 Data and data sources 
We used Norwegian population-based data when possible. Transition probabilities were based on an 
observational study including 2049 patients diagnosed with CRC from 1993 to 2010 at Oslo University 
Hospital (referred to as OUS data) [8, 9]. The sample was population-based, and their ages correspond to 
CRC patients in general. The OUS data were also used to identify those treated with resection during 
primary treatment. Information from the Norwegian Patient Registry (referred to as NPR data) from 2003 
and 2004, previously used in Aas et al. [10], was used to quantify hospital treatments, except primary 
surgical treatment, including hospital stays for complications and metastatic surgical treatment. The cost 
estimates from the NPR were average numbers and not adjusted for age. Radiotherapy and chemotherapy 
(both adjuvant and palliative) were based on treatment guidelines and expert opinions. Other data sources 
were national life tables, internationally published papers, and expert opinions (three co-authors – one 
surgeon, one oncologist, and one gastroenterologist). For complementary information about the 
assumptions and data used for the analyses not presented in the paper, see Online Resource 1.   
We used the individual-level OUS data to estimate rates of recurrence, disease-free survival, and overall 
survival. We controlled for age and gender in the estimations, and for the model we predicted the rates for 




The cost inputs for the treatments provided during the first year are presented in Online Resource 1, and 
the cost input of palliative chemotherapy is shown in Table 9 in Appendix 1 of Joranger et al.[5].  
 
The probability of receiving an R0-resection after recurrence and all the conditional probabilities on the 
right side of squares A and Q in Figure 2 were based on expert opinion [5]. To estimate QALYs, we 
assumed that the health-related quality of life (HRQoL) for patients with CRC and those without CRC 
was 0.74 and 0.80, respectively [11, 12].  
We applied a 4% discount rate for costs, overall survival, and QALYs. In addition, we ran a separate 
analysis with zero discounting for overall survival [13, 14]. All cost were estimated in euros (€1 = NOK 
7.79) and adjusted to 2016 euros using the consumer price index (2.62% for the period 2011–2016).  
The Norwegian guidelines for economic evaluation of health interventions [13] recommend using NOK 
500,000 per life year in full health (1 QALY) for analyses across sectors. Adjusted for inflation (2.34% 
yearly) [15], the Norwegian WTP threshold per QALY gained was then calculated to be €82,800 in 2016 
euros.  
This value was also used as a proxy for the WTP for a life-year gained.  
 
2.3 Estimation of costs and cost-effectiveness 
The estimation of the total treatment cost (output) was mainly based on the CRC stage at the time of 
diagnosis, the recurrence rate for each stage, the type of recurrence, the probability of re-recurrence, the 
probability of receiving palliative chemotherapy, the probability of receiving certain kinds of palliative 
chemotherapy, the distribution between colon and rectal cancer in the population at different stages, the 
compliance when following up and completing chemotherapy, and the survival time.  
 
For the analysis on changing treatment regarding chemotherapy and screening, we estimated the 
incremental cost, and for analysing the effect of reduced recurrence rate and the cost-effectiveness of 
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overall CRC treatment, we used the incremental cost-effectiveness ratio (ICER), which is defined by the 
differences in costs relative to differences in health outcomes.  
 
The total cost of CRC treatment and the cost-effectiveness of overall CRC treatment was estimated by 
comparing the treatment for an average 70-year-old CRC patient (defined as the “base case”) to a 
population without CRC. For all the analyses of changes in treatment, the changes were compared with 
the base case.  
 
2.4  Validation and uncertainty analysis 
The model has been validated by [5] for face, internal, cross, and external validity. The external validation 
for relative survival was based on data from The Cancer Registry of Norway. The validation concluded 
that a satisfactory match was found with other models and real-life observations for both costs and 
survival time without any preceding calibration of the model. Because the model was partly based on data 
from 1993–2010, the validation was also done against observations and models based on data from the 
same time period.   
We used one-way and multi-way sensitivity analyses to explore parameter-, methodological-, and model-
structure uncertainty. To explore the total uncertainty concerning the use of expert opinion, we used 
probabilistic sensitivity analysis (PSA). In the PSA, we gave beta distributions to all the parameters based 
on expert opinions and assumed that the upper level of the 95% confidence interval was +30% of the 
expected value and that the lower was −30%. To explore the uncertainty in the estimation of survival for 






3.1 Base case cost and survival  
3.1.1 Costs according to disease stage  
From a healthcare perspective, the total expected lifetime CRC costs and loss of life years (LYs) were 
reported for an average 70-year-old CRC patient according to the disease stage at the time of diagnosis 
(Table 2). Based on our model, a 70-year-old CRC patient had an expected lifetime CRC cost of €47,300. 
The expected costs increased with TNM stage as follows: stage I, €26,630; stage II, €38,130; stage III, 
€56,800; and stage IV, €69,890.  
 
Table 2   
 
3.1.2 Type and phase of treatment    
The treatments with the greatest impact on total lifetime costs (Table 2) were surgery of the primary 
tumour (€20,390) and palliative chemotherapy (€10,920). Costs related to diagnostic examinations, 
adjuvant treatment, and follow-up in general were modest for all stages. For stage IV, the main costs were 
“surgery – major resection” (primary tumour) (€19,230), “surgery - other” (€21,660), and “palliative 
chemotherapy” (€25,260). The palliative chemotherapy cost estimates were for the average patient that 
started with some kind of palliative chemotherapy treatment, and their treatment is shown in Figure 2. 
“Surgery – major resection” was the major cost component for stages I and II. Variations between stages 
depended on differences in treatment, the mix of colon and rectum cases, and the proportion of patients 
experiencing cancer recurrence. 
When we categorised treatment costs according to clinical pathway, starting with primary examinations 
and ending with palliative chemotherapy (Table 2), expected lifetime costs varied according to TNM stage 
at the time of diagnosis. Patients in stage IV had the highest expected costs both for primary treatment 
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(€42,050) and palliative treatment (€25,260), while patients in stage III had the highest expected costs of 
treatment for recurrence (€6360).   
 
The expected treatment cost of only the chemotherapy for the group of CRC patients receiving some kind 
of palliative chemotherapy was on average €40,850 per patient. This was estimated by multiplying the 
probability (in parentheses) of receiving the various treatment options shown in Figure 2 with the costs of 
the respective chemotherapy regimens given in Table 1 in Online Resource 2. These estimates were then 
summarized to provide the expected total costs for these various treatments. Of this, epidermal growth 
factor receptor inhibitors (EGFR-inh) such as cetuximab/panitumumab and the related 3rd line treatment 
with irinotecan in Figure 2 jointly constituted 36.0% of the costs (equal to the sum of the 3rd line 
scenarios in Table 2 in Online Resource 2), and bevacizumab and the related treatment FLIRI/FLOX 
jointly (both branch C, D and F, G in Figure 2) constituted 34% of the costs (equal to the sum of 27.5%, 
3%, 3%, 0.3%  in Table 2 in Online Resource 2). Table 3 in Online Resource 2 shows the total treatment 
cost per patient when receiving all of the chemotherapy treatments in one separate scenario/branch 
defined in Figure 2. Costs were estimated for seven different branches, where the most expensive 
branches (C, D, and E in Figure 2) cost €97,000 euro. Of the total cost of palliative CRC chemotherapy, 
this branch generated 40.7% of the cost when we adjusted for which treatment the patients actually 
received and the proportion of patients who did not undergo all treatments (equal to the sum of the first 
row in Table 2 in Online Resource 2).  
 
 
3.1.3 Recurrence and palliative chemotherapy 
 
Variations in treatment costs for a patient could also be estimated according to certain low- and high-cost 
treatment pathways. In the low-cost treatment pathway (stage I patients), we included the following cost 
components: (i) diagnostics, (ii) resections without complications, and (iii) five-year follow-up. In the high-
cost estimate (patients with recurrence), we included (i) diagnostics (ii) treatment costs in the first year, (iii) 
one-year follow-up, (iv) one-year treatment for recurrence in the second year after being diagnosed with 
CRC, (v) one-year follow-up after recurrence for those who achieved R0, and (vi) palliative chemotherapy 
at the end of the second year, at the end of the third year, and at the end of the fourth year. The 
13 
 
combination of palliative chemotherapy included in the high-cost treatment pathway was bevacizumab + 
FLIRI in the 1st line, FLOX in the 2nd line, and EGFR-inh + irinotecan in the 3rd line. 
 
The expected costs for a low-cost-treatment pathway (stage I without recurrence) were estimated to be 
€16,450, and the expected costs for a high-cost-treatment pathway (with recurrence) were €125,830 and 
€142,540 for patients in stages I and IV, respectively (Table 2).  
3.1.4 Survival, QALYs, and years lost 
According to the model, the life expectancy for a CRC patient diagnosed at the age of 70 years was 9.3 
years (7.0 years with discounting), implying a loss of 6.3 years (4.1 years discounted) compared to an 
average 70-year-old Norwegian (Table 2).  The loss of discounted QALYs was 3.7 on average and 1.4, 2.6, 
3.8, and 7.9 for stage I, II, III, and IV, respectively. Based on the model, we found that life expectancy was 
14.0 years (1.6 years lost) for a patient in stage I and 1.5 years (14.1 years lost) for a patient in stage IV.  
3.1.5 Uncertainty 
According to the deterministic sensitivity analysis, for most input parameters the model was insensitive to 
a 20% change. The expected total costs were most sensitive to changes in frequency of surgery and the 
use of bevacizumab in palliative treatment (see Online Resource 3). 
We performed a PSA to simultaneously account for all uncertainty caused by parameters based on expert 
opinion and found that the 95% credible interval (CrI) for the total costs was ±3% of the mean, and for 
the effect on life expectancy the 95% CrI was ±0.5% of the mean (see Online Resource 3).  
 
3.2 Changing treatment strategies  
3.2.1 Scenarios of palliative chemotherapy 
When health authorities estimate the costs of introducing new and costly drugs, such as EGFR-inh or 
bevacizumab, they may assume that 100% of the CRC patients will receive the treatment. Our analyses 
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considered that these drugs were only relevant to subgroups of CRC patients [16, 17]. We assumed that 
61% of all 70-year-old patients diagnosed at stage IV, or experiencing recurrence after R0 resection, would 
receive palliative chemotherapy [17]. The different treatment paths and related probabilities are shown in 
Figure 2, and costs per treatment are shown in Table 1 in Online Resource 2. To account for higher 
compliance, we estimated the cost per patient (undiscounted) when fully treated according to the defined 
palliative chemotherapy scenarios compared to no palliative treatment (see Figure 2 and Online Resource 
2). The cost difference between the full treatment scenario “5-FU/FA (1st line) and EGFR-inh + irinotecan 
(2nd line)” (Q, R in Figure 2) (€52,030) and the scenario “bevacizumab and FLIRI (1st line), FLOX (2nd line), 
and EGFR-inh + irinotecan (3rd line)” (C, D, E) (€97,000), which represents the strategy with bevacizumab, 
was €44,970 (see Table 3 in Online Resource 2). Furthermore, we found that using “bevacizumab and 
FLIRI” (C) rather than only “FLIRI” (J) in the 1st line would have an extra cost of €33,030 (see Table 3 in 
Online Resource 2).  
 
  Alternative chemotherapy schedules (protocols) – impact on costs 
To show the importance of uncertainty in the input data and the possible impact of future decisions, we 
estimated the effect of changes in both prices and probabilities (see Table 1 in Online Resource 4). The 
use of bevacizumab varies between different countries. In the model, we assumed that 29% of patients 
receiving palliative chemotherapy were treated with this drug. We estimated the cost difference from the 
base case for the following new scenarios (treatment changes 1–4 in Table 3): 
1. All patients who receive palliative chemotherapy are treated with bevacizumab (all patients move 
through box B in Figure 2).  
2. No patients receive bevacizumab (all patients going through box B in the base case move instead 
through I in Figure 2). 
3. Patients receiving combination chemotherapy (FLIRI/FLOX) as the 1st line of treatment in the 
base case instead receive bevacizumab and FLIRI/FLOX (all patients who move through I in the 
base case move instead through B). 




The treatment alternatives most sensitive to changes in treatment costs were the “EGFR-inh 
(cetuximab/panitumumab) +irinotecan treatment” and “bevacizumab + FLIRI treatment” (see Table 3). If we e.g. 
assume alternative 1 in Table 3 (All patients getting palliative chemotherapy receive bevacizumab), the expected total 
costs for a CRC patient would increase by 14%. This change in treatment strategy would thus increase the 
treatment costs in Norway by €27.8 million per year (assuming 4268 diagnosed CRC patients per year) and 
by €5.3 per capita per year. If bevacizumab was not offered (FLOX and FLIRI was used without bevacizumab, 
alternative 2), the expected total costs would decrease by 5% compared to the current strategy, and the 
Norwegian health sector's expenditure would decrease by €10.9 million (€2.1 per capita). If those receiving 
“FLIRI/FLOX” as a 1st line of treatment were instead to receive “bevacizumab + FLIRI/FLOX” 
(alternative 3), then the costs would increase by 8% per patient and increase the health sector's 
expenditure in Norway by €16.3 million (€3.1 per capita).    
 
Table 3   
 
 Increased use of chemotherapy in the elderly 
CRC is common in elderly patients, and approximately 40% of CRC patients are 75 years of age or older. 
What then would be the effect on CRC costs of treating a greater number of elderly patients with 
palliative chemotherapy? One extreme scenario would be to assume that all patients would receive 
palliative chemotherapy. We estimated the change from the base case by analysing the following scenarios 
(treatment change 5-8 in Table 3): 
5. All patients who are not disease free after treatment receive palliative chemotherapy (more 
patients move into the sub-model illustrated by Figure 2). 
6. Given we are in scenario 5 above, all patients in this scenario receive bevacizumab as a 1st line of 
treatment (all patients receiving palliative chemotherapy move through box B in Figure 2). 
7. Ten percentage points compared to base case move from 5FU/FA-treatment (often elderly 
patients) to combination chemotherapy with bevacizumab (10 percentage points move from box 
P to B). 
16 
 
8. Ten per cent more CRC patients receive palliative chemotherapy among those diagnosed with 
stage IV or recurrence. 
One extreme scenario above is number 5 – all patients who are not disease free after treatment would 
receive palliative chemotherapy regardless of age and general health. Based on the current pattern of 
chemotherapy prescription, the costs for an average CRC patient would increase by 9% (Table 3). If all 
patients received “bevacizumab as a 1st line of treatment” (scenario 6), the expected total costs would increase 
by 29%, and the health sector's expenditure would increase by €58.2 million (€11.1 per capita).    
 
3.2.2 Reduced recurrence rate  
Recurrence of cancer implies more treatment and greater loss of life expectancy. We assumed a 5 
percentage point reduction in the 10-year recurrence rate from 32.5% (base case) to 27.5% for stages I–
III. To achieve this, we used the same percentage reduction in the transition probabilities moving patients 
from the state of ‘disease free’ to the state of recurrence for all years and for all three stages. All other 
inputs were as in the base case. Reduced recurrence rate reduced the treatment costs because of fewer 
surgeries and other treatments for recurrence, less palliative treatment, and a reduced number of patients 
for follow up after recurrence. However, reduced recurrence also caused more patients to complete the 
follow up after the primary treatment. Furthermore, reduced recurrence caused increased survival. 
According to the model, the 5 percentage point reduction described above would reduce the costs by 
€2190 per patient (5.3%) and increase the overall survival by 0.68 years (0.43 years discounted). Out of the 
4268 persons diagnosed with CRC in 2015, 80% were diagnosed with stage I, II, or III disease (OUS 
data). Hence, a reduction in the recurrence rate would imply 2310 LYs saved per year in Norway (0.68 
years * 4268 CRC patients * 0.80) and reduce health care costs by €7.47 million per year (€1.44 per capita).     
Given the Norwegian WTP threshold per QALY gained, society’s willingness to pay for interventions that 
could contribute to a 5 percentage point reduction in recurrence was €28,540 per CRC patient when 
survival was discounted by 4% per year (€2190 + [0.43 year * 0.74 QALYs per LY * €82,800 per QALY) 
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in stage I, II, or III (€43,850 with undiscounted survival). In total, this account for €97 million per year 
(€28,540 per patient * 4268 patients per year * 0.80 in stage I, II, or II) and €18.8 per capita.  
 
 
Table 4  
 
 
3.2.3 Primary prevention 
Prevention of CRC might be achieved by screening and removing precursor lesions, increased physical 
activity, modifications to diet and lifestyle (including smoking cessation and prevention of excessive body 
weight), and use of anti-inflammatory drugs. Preventive measures might reduce the number of cases in all 
CRC stages, and the outcome of preventive intervention for CRC can be estimated using the model. In 
our analysis, we assumed that prevention affects all stages with the same percentage reduction in the 
number of people who develop CRC. Thus, we used the cost estimates of the four CRC stages as an 
estimate of the cost reduction of saving one person from developing CRC and used the estimation of loss 
of life years for the same stage to estimate the number of years saved. 
The reduction in costs caused by preventing one CRC case was estimated to be €47,300; see Tables 2 and 
4. In addition, according to the model, each CRC case prevented gained 6.3 years (4.1 years discounted). 
Given the WTP threshold value, society's willingness to pay for preventive interventions was estimated to 
be €353,660 per CRC case prevented (€47,300 + [3.7 QALY * €82,800 per year]) when survival was 
discounted by 4%.  
3.2.4 Screening – gain from stage migration 
To assess the effect of stage migration on healthcare costs, we used CRC screening as an example. 
Randomised controlled trials have been carried out for CRC screening in several countries, and our model 
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estimates were based on results from the UK and Denmark [18, 19]. In both trials, faecal occult blood 
tests were used to detect cancer at an early, asymptomatic stage in order to improve survival and reduce 
the CRC treatment costs. Table 2 in Online Resource 4 shows that CRC patients diagnosed through a 
screening programme have a more favourable stage distribution than those in the control groups. This is a 
potential gain from screening, provided that the early-stage, screen-detected tumours do not represent 
overdiagnosis, e.g., tumours that would never have emerged as clinical tumours within the lifespan of the 
person. The stage migration effect was greater in the UK trial than in the Danish trial. Patients in the 
screening groups were 50–74 years old and 45–74 years old, respectively, in these trials. 
Applying data from Denmark [19], the reductions in costs were €14.9 per screened individual and €7300 
per CRC detected (both excluding the cost of screening). The corresponding results based on the UK trial 
[18] were €21.6 and €10,306, respectively. The changes in cost caused by screening were a result of stage 
migration from more advanced cancer when diagnosed due to symptoms (base case) to a less advanced 
and even pre-cancerous stage when detected pre-symptomatically at screening. In the model, stage 
migration reduced both the cost of primary treatment and the number of recurrences. When fewer 
patients were diagnosed with cancer at stages III and IV and did not experience recurrence, the number of 
patients receiving palliative treatment decreased. In cases where screening results in excessive 
overdiagnosis of early and non-cancerous lesions, the consequences for costs will be more complex.   
3.3  Productivity in CRC treatment 
To estimate the productivity of CRC treatment in general, we need to quantify the survival gained by CRC 
treatment. Therefore, we used the estimated life expectancy according to CRC stages (Table 2), compared 
this value to the life expectancy for a cohort of hypothetical patients without any CRC treatment, and 
estimated the gain to society per euro used for CRC treatment. Online Resource 5 presents the analysis of 
survival without CRC treatment as well as the model and the assumptions used. 
 
We have not found any relevant survival data for a patient without treatment. Instead, we used a separate 
Markov model to estimate the survival for the group (see Online Resource 5). In this model, we followed 
the patients from the age of 70 years to 100 years or until death, and we assumed the following transition 
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probabilities from one stage to another: stage I to stage II 0.583 (CI used in the PSA: 0.3–0.9) per year, 
stage II to stage III 0.656 (0.3–0.9), and stage III to stage IV 0.747 (0.31–0.85). The assumptions were 
based on the literature, where the transition probabilities were estimated using calibrations[20-22]. For 
patients in stage IV, we assumed the total annual probability of CRC death and non-CRC death to be 
0.582.  
 
The gain in LYs from the overall CRC treatment was estimated to be 6.05 years. For all stages, and given 
the Norwegian WTP threshold per QALY, the gain was €5.2 per euro used for CRC treatment (€7.8 if 
survival was not discounted). For stages I, II, and III, the gain per euro used for CRC treatment was 
€12.7, €8.1, and €5.0, respectively.   
 
These estimates depended partly on the estimated life expectancy for a cohort of hypothetical non-treated 
CRC patients, estimated separately with a Markov model. The parameter uncertainty for the transition 
parameters between CRC stages used in this separate model was considerable. Thus, we performed a PSA 
for this separate Markov model, and based on the upper level of expected survival time for untreated 
patients we estimated the gain for society to be €5.5 per euro used for CRC treatment and €3.6 when 





4.1 The results of the analyses 
The estimated lifetime healthcare cost for an average 70-year-old CRC patient was €47,300 and varied 
with disease stage at diagnosis from €26,630 to €69,890. Compared with the empirical (“model-free”) 
Norwegian study by Aas [10], our overall cost estimate was 39% higher, but only 1.3% higher after 
adjusting for differences in the included costs and time horizon (see more in [5]). The increase in costs 
according to the disease stage was similar to increases reported by Ladabaum et al. [23] and Frazier et al. 
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[21], while Brown et al. [24] found an increase in costs for stages I–III, but a decrease for stages IV. 
However, comparing our CRC cost with those in non-Norwegian studies is difficult because of 
differences in unit costs and assumptions for the analyses [25]. Nevertheless, we compared our results 
with those of a recent Irish study by Tilton et al. that described the treatment regime and other important 
conditions in such detail that it allowed for adjustment based on relevant differences [26]. When adjusting 
for the exchange rate, the annual Irish inflation between 2008 and 2011, and important differences in unit 
prices and treatment regimens between the two studies, the cost difference between Tilton’s model and 
our model was −3.0%, −1.3%, 3.6%, and −1.2% for stages I, II, III, and IV, respectively, all within the 
estimated credible intervals of the former study (see more in [5]).  
The cost for CRC treatment estimated by the model appeared modest compared to the number of 
QALYs gained by the same treatment. For all stages and given the Norwegian WTP threshold per QALY 
gained, the gain to society was €5.2 per euro allocated for CRC treatment and €12.7, €8.1, and €5.0 for 
stages I, II, and III, respectively, per euro allocated for CRC treatment. These estimates depended heavily 
on the estimated survival time for non-treated patients (Online Resource 5, Fig. 2). However, the gain 
would still be €3.6 per euro spent on treatment for all stages despite using the lower level of the estimated 
CrI. The public health service in Norway is often criticised for high costs, but our results indicate that the 
surplus to society seems to be considerable for CRC treatment.  
A 20% change in the cost of the various palliative chemotherapies, including, for example, drug costs and 
time-use costs, had a minor effect on the total CRC costs (<2%), while expanded use of palliative 
chemotherapy could increase the total costs up to 29% (€11.3 per capita). Two factors are especially 
important for a possible increase in cost – the use of bevacizumab or EGFR-inh and an increased use of 
palliative chemotherapy in elderly patients. The current trend to use EGFR-inh more frequently as a 1st 
line of treatment and the increased use of palliative chemotherapy in the elderly can therefore have a 
profound impact on cost [16, 27, 28]. Because many evaluations have time horizons of 10–30 years, PSA 
based on parameter probability distributions estimated from “yesterday’s data” can be misleading. 
Therefore, CRC evaluations with long time horizons need to not only focus on high-quality palliative 
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chemotherapy data, but also make reasonable assumptions about changes in future palliative treatments 
and perform sensitivity analyses based on these assumptions and alternative scenarios.     
We found that a 5 percentage point reduction in the 10-year recurrence rate for stages I–III would reduce 
CRC costs by €2190 per patient and increase overall survival by 0.68 years per patient. Based on these 
findings and the declared acceptable WTP threshold value of €82,800 per QALY gained, the Norwegian 
health sector should be willing to pay €97 million in total per year to achieve this reduction in recurrence 
rate (see Section 3.7). Approximately 3000 colorectal resections for malignancy are performed each year in 
Norway. Assuming that each colorectal surgeon should perform at least 15 resections each year to 
maintain their competence, a maximum of 200 surgeons is needed in this field [29]. A comprehensive 
training programme (initial colorectal surgery training and yearly follow-up training) could use modern 
educational tools (such as simulators, operations on animals, etc.) along with workshops and lectures by 
highly experienced and skilled colorectal surgeons, radiologists, and pathologists. Assuming that such a 
comprehensive training programme would cost €300,000 per surgeon and that the effect would be a 
reduction in recurrence rate by 5 percentage points, the investment would be paid back after only 11 CRC 
operations per surgeon.   
The estimates for a 5 percentage point reduction in the 10-year recurrence rate are also relevant when 
estimating possible gains from post-cancer prevention such as lifestyle interventions (diet, physical activity, 
etc.). Some studies show significant effects of such interventions [30-38], but these effects are highly 
uncertain because of the scarcity of high-quality randomised controlled trials [37, 38]. When evaluating 
strategies for post-CRC cancer prevention, we also have to consider the possible effects on HRQoL, 
physical functioning, tolerance to interventions, morbidity, and non-CRC mortality [37, 38]. 
For the screening analysis, the estimates did not consider that some patients diagnosed with CRC in the 
screening group would have died of something else before their CRC had produced symptoms if they had 
not been screened. This implies overtreatment for the screening group, where some of the CRCs were 
unnecessarily discovered, which adds extra costs for the screening group that were not included in our 
estimates. To include this in the analysis, we would need data indicating the proportion of the population 
with undiagnosed CRC who die from non-CRC causes.    
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4.2 Strengths and weaknesses of the general model  
The cycles in the model were set to one year. The precision level can be improved by shortening the cycle 
length, but this would make the model more complex and accentuate the trade-off between model 
complexity and accuracy. As a result of convex survival curves and half-cycle correction, we expected that 
this weakness would contribute to a slight overestimation of the mean survival.       
The cohort used in the model was diagnosed at the age of 70 years. This age might have resulted in a 
higher survival rate than if we had used the average age in the OUS sample. In [5], the average age for 
stages I–IV at the year of diagnosis was 69.9, 72.3, 70.4, and 70.5 years, respectively, in the OUS sample. 
When comparing these patients with our 70-year-old patients (based on Weibull regressions), we found 
that the differences in overall 10-year survival were −0.2%, 4.2%, 0.7%, and 0.03%, respectively, for the 
four stages. 
Another weakness of the analysis was that some of the data used were relatively old. The data on, for 
example, recurrence and resections were based on observations in the period 1993–2010, survival data in 
palliative phase were mainly based on data from 1995–2002, background mortality data were from 2009, 
and certain parts of the frequency estimates for metastatic surgery and medical treatment for 
complications were from 2003–2004. The estimates for the use of chemotherapy in the palliative phase 
and all unit costs were from 2011–2012. The validation of the model showed good correspondence with 
other models and studies from the same time period as our model [5]. The CRC mortality is currently 
lower than those estimated by the model, and the 5-year relative survival of CRC in Norway increased by 
7.7 percentage points from the period 1998–2007 to 2013–2017 (Cancer in Norway 2017). We see the 
same trend for metastatic CRC in Norway, which does not seem to be in line with the trend in the 
Netherlands where Hamers et al. [39] concluded that the overall survival of real-life stage IV patients did 
not improve from 2008 to 2016.  
 
The effects on total CRC cost of using relatively old data are uncertain because lower recurrence implies 
lower CRC cost due to fewer surgeries and reduced palliative chemotherapy, while increased use of more 
expensive drugs, particularly in the palliative phase, implies higher CRC cost. Further, if the threshold for 
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receiving surgical treatment for metastatic cancer has changed (most likely increased), our cost estimates 
would be too low, particularly for stage IV. In section 3.2.1, we showed the significance of changes in 
palliative chemotherapy and found that increased use of bevacizumab and EGFR-inh was of great 
importance for the overall treatment cost. It was therefore mitigating that the model's inputs for the 
palliative phase treatments were relatively up-to-date and based on expert opinions from 2011–2012. 
When developing the next version of the model, it will be important to update the input data. 
 
Rectal and colon cancers are different with regard to survival and treatment. Therefore, optimally the 
model should provide results for colon and rectum cancer separately. Even though we had access to a 
high-quality dataset to estimate recurrence rates, the dataset was too small to identify recurrence rates for 
rectal and colon cancer separately. Hence, the model was based on rectum and colon jointly. Further, in 
addition to estimating the cost of CRC one of the objectives of this study was to estimate the effect of 
changing treatment strategies. In palliation, this would not distinguish between rectal and colon cancers. 
Nevertheless, in the model we adjusted for rectal and colon cancer by weighing the proportion of rectal 
versus colon cases in all health states. In addition, we accounted for the fact that more rectal cancer 
patients are eligible for radiotherapy and separated out colon and rectum cases concerning frequencies and 
unit cost of resections (see Table 1 in Online Resource 1) in each of the Dukes stages. Although the 
model does not provide separate results for rectal and colon cancer, the model is capable of calculating 
these separately by making a model run for each cancer if the required data are available.  
 
Our study showed that the model's estimates of the total CRC cost are sensitive to changes in the 
chemotherapy treatment in the palliative phase. This means, for example, that in studies where we have to 
include future CRC costs (e.g., evaluation of screening), the uncertainty could be significant if the 
treatment strategies change a lot over time. 
 
Future development of the general model should also include more detailed HRQoL measures and 
improvements to the palliative part of the model. In addition, the effect of CRC on HRQoL in the 




The costs of CRC generally seem to be modest when comparing treatment cost and the number of years 
saved. The expected lifetime CRC costs increased with the stage of the disease at diagnosis and were 
higher among patient experiencing recurrence after a resection with a curative intent. Changes in the use 
of palliative chemotherapy had a major impact on the expected CRC costs. The current trend to use 
EGFR-inh more frequently as a 1st line of treatment and the increased use of palliative chemotherapy in 
the elderly can therefore have a profound impact on cost. Reducing the recurrence rate through improved 
surgical technique indicated a considerable cost-effectiveness potential.  
 
The different applications of the model illustrate its flexibility and indicate how the general model might 
be used to evaluate a broad range of interventions, making the model useful for researchers, health policy 















5-FU/FA: Nordic FLv = 5-fluorouracil/folinic acid; CI: Confidence interval; COI: Cost-of-illness; CRC: 
Colorectal cancer; CrI: Credible interval; EGFR-inh: Epidermal growth factor receptor inhibitors 
(cetuximab/panitumumab); FLIRI: A combination of Irinotecan and 5-fluorouracil/folinic acid; FLOX: A 
combination of Oxaliplatin and 5-FU/FA; FOBTs: Faecal occult blood tests; HRQoL: Health-related 
quality of life; LYs: Life years; NPR: National Patient Registry; OUS: Oslo University Hospital; PSA: 
Probabilistic sensitivity analysis; PS: Patient performance status; QALY: Quality adjusted life years; WTP: 
Willingness to pay. 
 
Online Resources 
Online Resource 1: Data input to the base case model 
Online Resource 2: Supplementary result for the base case model on chemotherapy costs 
Online Resource 3: Sensitivity analysis for the base case model 
Online Resource 4: Change in treatment strategies: data input and supplementary results 




Tables and figures 
 
Table 1  Overview of how decision-analytic models can be used to prioritise within and between 
diseases 
Compare Type of decision analysis Users of the results 
(i) Between 
diseases 







Explorative analyses to identify intervention 
strategies with considerable potential gains in 
order to target research and investments: 
• Willingness to pay for specific health 
improvements 
• Healthcare savings and costs of specific 
health improvements 
• Healthcare costs of altered treatments 
 
Researchers/innovators, 






strategies   









Table 2  Expected lifetime costs (€), survival time, and QALYs for a 70-year-old CRC patient 
compared with the population without CRC. 
  All stages Stage I Stage II Stage III Stage IV 
Per cent in each stage at diagnosis 100.0 17.8 36.3 25.7 20.2 
Total lifetime costs (€) 47,300 26,630 38,130 56,800 69,890 
Types of treatment  
   Preoperative diagnostics and staging (€) 2330 2160 2400 2680 1920 
   Surgery – major resection (€)  20,390 18,940 19,920 22,970 19,230 
   Surgery – other (€) 8230 1070 3240 9690 21,660 
   Adjuvant/neoadjuvant chemotherapy (€) 1530 30 600 4670 510 
   Radiotherapy (€) 1840 790 1800 3240 1080 
   Follow up, in total (€) 2060 790 3110 2880 230 
   Palliative chemotherapy (€) 10,920 2850 7070 10,680 25,260 
Phases of the treatment 
   Primary examination (€) 1880 1940 1870 1880 1860 
   Primary treatment (€)  28,830 19,290 21,800 34,990 42,050 
   Follow up first treatment (€) 1920 730 2950 2640 210 
   Examination and treatment of  
   recurrence (1st year with diagnosed  
   recurrence) (€) 3610 1750 4300 6360 500 
   Follow up after recurrence (€) 140 70 160 240 20 
   Palliative chemotherapy (€) 10,920 2850 7070 10,680 25,260 
Treatment pathways 
   Low estimate (Stage 1, no recur.) (€) 
 
16,450 19,420 26,720 
 
   High estimate (Full treatment including 
recurrence and bevacizumab) (€)  125,830 128,860 142,070 142,540 
Survival: Life years and quality-adjusted life years (QALYs) 
   Life years after diagnosis, undiscounted 9.3 14.0 11.5 9.0 1.5 
   Life years after diagnosis, discount. 4%  7.0 10.3 8.6 7.0 1.4 
   QALYs after diagnosis, discounted 4% 5.2 7.6 6.4 5.2 1.0 
   Life years lost, undiscounted 6.3 1.6 4.1 6.6 14.1 
   Life years lost, discounted 2% 5.1 1.2 3.2 5.2 11.6 
   Life years lost, discounted 4% 4.1 0.9 2.6 4.2 9.7 
   QALYs lost, discounted 4% a 3.7 1.4 2.6 3.8 7.9 
a The alternative assumed for the CRC patients is that HRQoL is similar to average people of the same age. 





Table 3  Change in expected lifetime costs (€) for a 70-year-old CRC patient compared with the base 
case  
Selected palliative chemotherapy treatment alternatives 




1. All patients on palliative chemotherapy receive bevacizumab 
13.8 6520 
2. No patients receive bevacizumab -5.4 -2550 
3. Patients who receive FLIRI/FLOX as the 1st line of treatment 
in the base case instead receive bevacizumab and FLIRI/FLOX 
8.1 3830 
4. Bevacizumab price from the pharmacy is reduced by 50% 
-2.3 -1100 
5. ‘All’ patients (including all elderly) not disease-free after 
treatment receive palliative chemotherapy 
9.4 4450 
6. All patients in scenario 5 above receive bevacizumab as the 1st 
line of treatment 
28.8 13,630 
7. Ten percentage points move from 5FU/FA-treatment (often 
old patients) to combination chemotherapy with bevacizumab 
2.0 930 
8. Ten per cent more CRC patients receive palliative 







Table 4  Treatment strategies, assumptions, costs, quality-adjusted life years (QALYs), life years (LYs), 
and willingness to pay (WTP) per person. Discounting is 4%, and all numbers are in €  





32.5% to 27.5% for 
stage I, II, and II in 
total.  





One CRC case 
prevented 




See the stage 
migration in Table 2 
in Online Resource 4  
14.9 per screened 
individual (21.6) 
7300 per CRC 
detected (10,306) 
   





See Online Resource 
5 
47,300   3.0 4.0 245,920  
(Gain of 
€5.2 per € 
invested) 
 





Fig. 1  Illustration of how the patient can move from one state to another in the model. 
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Fig. 2  The decision tree for palliative chemotherapy  
Legend to Figure 2: Conditional probabilities without brackets. The numbers in brackets show the 
probabilities of patients receiving the treatment in the box given that the patients receive some kind of 
palliative treatment. 5-FU/FA: Nordic FLv = 5-fluorouracil/folinic acid; EGFR-inh: Epidermal growth 
factor receptor inhibitors (cetuximab/panitumumab); FLIRI: A combination of Irinotecan and 5-FU/FA; 
FLOX: A combination of Oxaliplatin and 5-FU/FA; PS: Patient performance status. Reproduced from 
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